TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05817123

Intervention type: OTHER
Intervention: Questionnaires
Description: Administration of the following questionnaires:~* Mutuality scale~* Pittsburgh Sleep Quality Index (PSQI)~* Epworth Sleep Scale (ESS)~* Sleep Condition Indicator (SCI)~* International Physical Activity Questionaire (IPAQ)~* Mediterranean diet score (MDS)~* Quality of Life SF 12~* Hospital Anxiety and Depression Scale (HADS)

Intervention type: OTHER
Intervention: Questionnaires
Description: Administration of the following questionnaires:~* Mutuality scale~* Pittsburgh Sleep Quality Index (PSQI)~* Epworth Sleep Scale (ESS)~* Sleep Condition Indicator (SCI)~* International Physical Activity Questionaire (IPAQ)~* Mediterranean diet score (MDS)~* Quality of Life SF 12~* Hospital Anxiety and Depression Scale (HADS)
Study: NCT06401291

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Device consists of two electrodes that are applied to the chest region and are connected to a battery operated TENS (Frequency 80Hz, pulse width 150us and amplitude variable (patient dependent)). The device will be used a minimum of three times daily for 30 minutes and additionally during symptoms.
Study: NCT04793945

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: topical steroid and 308nm-Excimer light therapy
Description: applying topical steroid in combination with 308nm-Excimer light therapy to treat Alopecia Areata

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: topical steroid and 308nm-Excimer light therapy
Description: applying topical steroid in combination with 308nm-Excimer light therapy to treat Alopecia Areata
Study: NCT06104397

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written exercise guidance by neurologist
Description: Neurologists will provide written exercise education and guidance to their patients with Parkinson's Disease during neurologist visits and/or in after visit summary in the patient's EMR patient portal. The research team will facilitate the development of the written exercise guidance with input and feedback from each site's neurology, clinical, and administrative teams.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: A consultative model of physical therapy - a lower dose of physical therapy focused on physical activity and exercise promotion and coaching - will be implemented into each site. In the consultative model of physical therapy, visits are scheduled around needs of the patient, however will involve 1-4 additional visits within 3 months of evaluation and is based on personal factors that influence their exercise prognosis such as self-efficacy, readiness to change, fitness level, age, health literacy, comorbidities, and Parkinson's Disease-related motor and non-motor impairments.
Study: NCT06372535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan （dose 1）
Description: Participants would take 24-form simplified Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 8 weeks.~There were 10 minutes warm-up, 30 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan （dose 2）
Description: Participants would take 24-form simplified Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 16 weeks.~There were 10 minutes warm-up, 30 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan （dose 3）
Description: Participants would take 24-form simplified Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 24 weeks.~There were 10 minutes warm-up, 30 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan （dose 4）
Description: Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 8 weeks.~There were 10 minutes warm-up, 60 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan （dose 5）
Description: Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 16 weeks.~There were 10 minutes warm-up, 60 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan （dose 6）
Description: Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 24 weeks.~There were 10 minutes warm-up, 60 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan （dose 7）
Description: Participants would take 24-form simplified Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 8 weeks.~There were 10 minutes warm-up, 90 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan （dose 8）
Description: Participants would take 24-form simplified Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 16 weeks.~There were 10 minutes warm-up, 90 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan （dose 9）
Description: Participants would take 24-form simplified Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 24 weeks.~There were 10 minutes warm-up, 90 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training.
Study: NCT06039163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HH-120
Description: Participants randomized to active treatment in escalation phase will receive HH-120 administered via inhalation for 5 consecutive days (Day 1 to Day 5). Planned dose levels to be used for the escalation phase of the study are 50 (BID), 50 (TID), and 100 (BID) mg. The expansion phase will begin once the recommended dose for expansion phase determined, based on safety and preliminary efficacy data from the escalation phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants randomized to placebo group in escalation and expansion phase will receive placebo administered via inhalation for 5 consecutive days (Day 1 to Day 5).
Study: NCT05291507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muse MRgFUS System
Description: The intended use of the device is to thermally ablate breast tissue under magnetic resonance image guidance. The thermal ablation is performed non-invasively using extracorporeal focused ultrasound.
Study: NCT04976127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talineuren
Description: Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talineuren
Description: Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talineuren
Description: Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration
Study: NCT04632121

Intervention type: DRUG
Intervention: Nicorandil 20 MG
Description: Nicorandil is a nicotinamide ester that dilates peripheral and coronary resistance vessels via action on ATP-sensitive potassium channels and possesses a nitrate moiety that promotes systemic venous and coronary vasodilation. As a result of these dual actions, nicorandil reduces preload and afterload and results in an increase in coronary blood flow. In addition to these effects, nicorandil may have cardioprotective actions mediated through the activation of potassium channel
Study: NCT05378503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qsymia 3.75Mg-23Mg Extended Release Capsule
Description: From W0 to W2, once a daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qsymia 7.5Mg-46Mg Extended Release Capsule
Description: 1. From W2 to W14, once a daily.~2. At W14, if the weight loss rate is 3% or more, from W14 to W56(the end of visit), once a daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qsymia 11.25Mg-69Mg Extended Release Capsule
Description: At W14, if the weight loss rate is NOT 3% or more, from W14 to W16, once a daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qsymia 15Mg-92Mg Extended Release Capsule
Description: At W14, if the weight loss rate is NOT 3% or more, from W16 to W56(the end of visit), once a daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: From W0(Randomisation) to W56(the End of visit) once a daily.
Study: NCT05002803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program
Description: A Home-based Exercise Program to improve strength and balance and prevent falls.
Study: NCT05741697

Intervention type: DRUG
Intervention: bi-level ventillation
Description: non-invasive mechanical ventilation
Study: NCT06328088

Intervention type: DIETARY_SUPPLEMENT
Intervention: Non vegetarian
Description: Non vegetarian diet plus supportive treatment including lactulose and/or rifaximin

Intervention type: DIETARY_SUPPLEMENT
Intervention: Non vegetarian
Description: Non vegetarian diet plus supportive treatment including lactulose and/or rifaximin
Study: NCT04934358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical and motivational follow-up treatment
Description: Physical and motivational follow-up treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual rehabilitation program
Study: NCT06099535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01001 Dose A
Description: Capsules taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LNK01001 Dose A
Description: Capsules taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01001 Dose B
Description: Capsules taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LNK01001 Dose B
Description: Capsules taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Capsules taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Capsules taken orally
Study: NCT05658068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFE Spaces training and coaching
Description: Staff in facilities assigned to the intervention are eligible to receive evidence-based programming in suicide detection and prevention (Shield of Care; SOC) and wellness skill-building (Skills for Life) through training and personalized coaching. Multiple training sessions will be offered to small groups of staff in-person in residential facilities and paired with personalized in-person and virtual coaching.
Study: NCT05916209

Intervention type: PROCEDURE
Intervention: Peripheral nerve blocks
Description: Peripheral nerve blocks provide intense, site-specific analgesia administring local anesthetics near the nerves.

Intervention type: PROCEDURE
Intervention: Peripheral nerve blocks
Description: Peripheral nerve blocks provide intense, site-specific analgesia administring local anesthetics near the nerves.
Study: NCT06101498

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Akut kidnet injury(AKI)
Description: postoperative 24 hours

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Akut kidnet injury(AKI)
Description: postoperative 24 hours

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Akut kidnet injury(AKI)
Description: postoperative 24 hours
Study: NCT05318664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: 20 minutes of cryotherapy on the dominant shoulder with ice bags
Study: NCT05948085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 10 mg IN
Description: All participants will receive zavegepant 10 mg IN spray in period 1 and a butterscotch candy + zavegepant 10 mg IN spray in period 2
Study: NCT05884593

Intervention type: DEVICE
Group type: OTHER
Intervention: Pedicle screw instrumentation using Mazor X robotic system
Description: Pedicle screw instrumentation using Mazor X robotic system
Study: NCT04909944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel Supraglottic insertion
Description: i-gel Supraglottic insertion for oxygenation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Suction Disposable Supraglottic insertion
Description: Laryngeal Tube Suction Disposable Supraglottic insertion for oxygenation
Study: NCT06054841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postpartum follow up card
Description: The intervention will consist of a card given to patients at time of discharge. One side of the card will list the patient's name and a list of recommended postpartum follow-up appointments based on their diagnoses at the time of discharge. The back of the card will list relevant phone numbers to assist patients with scheduling.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No deviation from standard discharge education
Study: NCT05216484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
Description: the third dose immunization schedule of SARS-CoV-2 inactivated vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
Description: the third dose immunization schedule of SARS-CoV-2 inactivated vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
Description: the third dose immunization schedule of SARS-CoV-2 inactivated vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
Description: the third dose immunization schedule of SARS-CoV-2 inactivated vaccine
Study: NCT05143463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS101 IV infusion
Description: Approximately 1 hour prior to start of study drug infusion, an IV port will be inserted into the antecubital region and a sterile normal saline solution infusion will be initiated at fixed rate in order to keep the vein open. The study drug will be infused over approximately 60 minutes at a constant rate. At the end of the infusion, 3 mL of saline solution will be injected to flush the remaining drug into the IV catheter. The end of infusion will be set to the end of the 3 mL flush. For safety reason (e.g., administration of rescue medication), the IV line will remain opened for approximately 1 hour following completion of infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NS101 IV infusion
Description: Approximately 1 hour prior to start of study drug infusion, an IV port will be inserted into the antecubital region and a sterile normal saline solution infusion will be initiated at fixed rate in order to keep the vein open. The study drug will be infused over approximately 60 minutes at a constant rate. At the end of the infusion, 3 mL of saline solution will be injected to flush the remaining drug into the IV catheter. The end of infusion will be set to the end of the 3 mL flush. For safety reason (e.g., administration of rescue medication), the IV line will remain opened for approximately 1 hour following completion of infusion.
Study: NCT06359899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0901 capsule
Description: Active Substance: AK0901, Pharmaceutical Form: Capsule, Route of Administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
Study: NCT06447636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib: 250mg qd，d1-21, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab：200mg ivdrip, d1, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2，iv drip for 2h，d1, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S1：40\~60mg Bid，d1\~14, q3w
Study: NCT05210751

Intervention type: OTHER
Intervention: Physical and psychosocial assessments
Description: Dual Task Test, 6 min Walking Test, the Baecke Habitual Physical Activity Questionnaire, Multidimensional Fatigue Inventory-20, Tracking Test, General Self-Efficacy Scale the Toronto Alexithymia Scale, the Revised FM Impact Questionnaire, the Social Support Scale.

Intervention type: OTHER
Intervention: Physical and psychosocial assessments
Description: Dual Task Test, 6 min Walking Test, the Baecke Habitual Physical Activity Questionnaire, Multidimensional Fatigue Inventory-20, Tracking Test, General Self-Efficacy Scale the Toronto Alexithymia Scale, the Revised FM Impact Questionnaire, the Social Support Scale.
Study: NCT05930886

Intervention type: OTHER
Intervention: Focus Group
Description: Black or Hispanic/Latino parents, caregivers or family members of children with ADHD symptoms and/or emotional dysregulation, will discuss: (1) impact of child's mental health, treatments, care received; (2) perceived and actual barriers to future study participation, including discussion about acceptability of bio-specimen collection methods for urine and blood. Each group will comprise individuals who self-identify as Hispanic/Latino, Black, or mixed race. Groups are anticipated to comprise individuals who identify with one or the the other race/ethnicity in order to create space to hear perspectives that may differ between these broadly defined groups.

Intervention type: OTHER
Intervention: Focus Group
Description: Black or Hispanic/Latino parents, caregivers or family members of children with ADHD symptoms and/or emotional dysregulation, will discuss: (1) impact of child's mental health, treatments, care received; (2) perceived and actual barriers to future study participation, including discussion about acceptability of bio-specimen collection methods for urine and blood. Each group will comprise individuals who self-identify as Hispanic/Latino, Black, or mixed race. Groups are anticipated to comprise individuals who identify with one or the the other race/ethnicity in order to create space to hear perspectives that may differ between these broadly defined groups.
Study: NCT05583630

Intervention type: DEVICE
Intervention: A gap plate with the function of knee joint pressure detection
Description: A gap plate can measure knee joint pressure by tension sensor. This is a part of routine medical care.
Study: NCT05782153

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention A (hearing aid self-fitting with direct adjustment)
Description: The intervention offered is a hearing aid fitting with the Lexie B2 Powered by Bose receiver-in-the-canal hearing aids using a self-fitting strategy with direct adjustment. The hearing aids will be accompanied and operated with the Lexie smartphone application. Participants will complete a hearing screening (at 500, 1000, 2000 and 4000 Hz) called Hearing Check on the Lexie smartphone application, which will be used to tune the hearing aids according to frequency and loudness level. Participants will be able to use two wheels to change the loudness and fine-tune the hearing aids. Participants will wear the hearing aids for four weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention B (hearing aid self-fitting with in-situ fitting)
Description: The intervention offered is a hearing aid fitting with the Lexie B2 Powered by Bose receiver-in-the-canal hearing aids using the in-situ audiometry fitting strategy. The hearing aids will be accompanied and operated with the Lexie smartphone application. Participants will complete an in-situ audiogram on the Lexie app, which enables the measurement of hearing thresholds through the hearing aids (at 500, 1000, 2000 and 4000 Hz). The hearing aids will then be self-programmed according to the participant's in-situ audiogram with a proprietary fitting algorithm that is based on NAL-NL2. Participants will wear the hearing aids for four weeks.
Study: NCT05673395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolyzed alkaline reduced water generator
Description: Participants drink water (10 mL/kg body weight) generated from the device after intensive excercise.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electrolyzed alkaline reduced water generator
Description: Participants drink water (10 mL/kg body weight) generated from the device after intensive excercise.
Study: NCT06009757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GUIDEX® guiding catheter
Description: The main steps of the procedure Percutaneous Coronary Intervention are :~* The patient should prepare for angioplasty using standard techniques. Appropriate anticoagulation and vasodilation therapy should be administered.~* The Guiding Catheter must be introduced into the vascular system by cut-down or percutaneous techniques.~* The guiding catheter will be introduce over a previously placed standard angiographic wire. It will be aspirate and flush after the removal of the angiographic wire following established angiographic technique.~* The catheter should should address the selected vascular site~* The guiding catheter will be removing. The procedure is performed in a healthcare facility, in an operating room under fluoroscopic monitoring. The users are trained practiticoners for PCI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Launcher™ coronary guide catheter
Description: The main steps of the procedure Percutaneous Coronary Intervention are :~* The patient should prepare for angioplasty using standard techniques. Appropriate anticoagulation and vasodilation therapy should be administered.~* The Guiding Catheter must be introduced into the vascular system by cut-down or percutaneous techniques.~* The guiding catheter will be introduce over a previously placed standard angiographic wire. It will be aspirate and flush after the removal of the angiographic wire following established angiographic technique.~* The catheter should should address the selected vascular site~* The guiding catheter will be removing. The procedure is performed in a healthcare facility, in an operating room under fluoroscopic monitoring. The users are trained practiticoners for PCI.
Study: NCT05244564

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR)
Description: Walk and talk therapy, walking on a treadmill while talking with a therapist about self-chosen pictures representative of one's trauma; 3MDR also includes some features of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR) therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR)
Description: Walk and talk therapy, walking on a treadmill while talking with a therapist about self-chosen pictures representative of one's trauma; 3MDR also includes some features of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR) therapy.